LIVER

Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C

A K P Lim¹, S D Taylor-Robinson², N Patel³, R J Eckersley¹, R D Goldin⁴, G Hamilton³, G R Foster^5,*, H C Thomas⁵, D O Cosgrove¹, M J K Blomley¹

¹ Imaging Sciences Department, MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK
² Imaging Sciences Department, MRC Clinical Sciences Centre and Department of Medicine A, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK, and Department of Medicine, Faculty of Medicine, Imperial College London, St Mary’s Hospital, London UK
³ Imaging Sciences Department, MRC Clinical Sciences Centre and Department of Medicine A, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK
⁴ Department of Histopathology, Faculty of Medicine, Imperial College London, St Mary’s Hospital, London, UK
⁵ Department of Medicine, Faculty of Medicine, Imperial College London, St Mary’s Hospital, London, UK

Correspondence to:
Correspondence to:
Dr A K P Lim
The Robert Steiner MR Unit, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK; a.lim{at}ic.co.uk

Background and aims: A reliable non-invasive assessment of the severity of diffuse liver disease is much needed. We investigated the utility of hepatic vein transit times (HVTT) for grading and staging diffuse liver disease in a cohort of patients with hepatitis C virus (HCV) infection using an ultrasound microbubble contrast agent as a tracer.

Materials and methods: Eighty five untreated patients with biopsy proven HCV induced liver disease were studied prospectively. All were HCV RNA positive on polymerase chain reaction testing. Based on their histological fibrosis (F) and necroinflammatory (NI) scores, untreated patients were divided into mild hepatitis (F 2/6, NI 3/18), moderate/severe hepatitis (3 F <6 or NI 4), and cirrhosis (F = 6/6) groups. In addition, 20 age matched healthy volunteers were studied. After an overnight fast, a bolus of contrast agent (Levovist) was injected into an antecubital vein and spectral Doppler signals were recorded from both the right and middle hepatic veins for analysis. HVTTs were calculated as the time from injection to a sustained rise in Doppler signal >10% above baseline. The Doppler signals from the carotid artery were also measured in 60 patients and carotid delay times (CDT) calculated as the difference between carotid and hepatic vein arrival times. The earliest HVTT in each patient was used for analysis.

Results: Mean (SEM) HVTT for the control, mild hepatitis, moderate/severe hepatitis, and cirrhosis groups showed a monotonic decrease of 38.1 (2.8), 38.8 (2.4), 26.0 (2.4), and 15.8 (0.8) seconds, respectively. Mean (SEM) CDT for the control, mild hepatitis, moderate/severe hepatitis, and cirrhosis patients again showed progressive shortening of 30.3 (2.6), 25.9 (2.6), 14.8 (2.1), and 5.6 (1.2) seconds, respectively. There were significant differences between the groups for HVTT (ANOVA, p<0.001) and CDT (ANOVA, p<0.001). There was 100% sensitivity and 80% specificity for diagnosing cirrhosis and 95% sensitivity and 86% specificity for differentiating mild hepatitis from more severe liver disease.

Conclusion: We have shown, for the first time, that HVTT using an ultrasound microbubble contrast agent can assess HCV related liver disease with clear differentiation between mild hepatitis and cirrhosis. There were significant differences between these two groups and the moderate/severe hepatitis group. CDT offers no additional benefit or greater differentiation than HVTT and can be omitted, thus simplifying this technique. HVTT may complement liver biopsy and may also be a useful alternative for assessment of liver disease in patients who have contraindications to biopsy.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; APRI, ratio of serum AST/platelet count; CDT, carotid delay time; F, fibrosis; HCV, hepatitis C virus; HVTT, hepatic vein transit time; NI, necroinflammatory; PCR, polymerase chain reaction

Keywords: ultrasound; microbubbles; hepatitis C; liver; tracer studies; functional studies

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Digest

Robin Spiller
Gut 2005 54: 1. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• ZHOU, J H, LI, A H, CAO, L H, JIANG, H H, LIU, L Z, PEI, X Q, HAN, F (2008). Haemodynamic parameters of the hepatic artery and vein can detect liver metastases: assessment using contrast-enhanced ultrasound. Br. J. Radiol. 81: 113-119 [Abstract] [Full Text]  
• Lim, A. K. P., Patel, N., Hamilton, G., Mylvahan, K., Kuo, Y.-T., Goldin, R. D., Taylor-Robinson, S. D. (2007). 31P MR Spectroscopy in Assessment of Response to Antiviral Therapy for Hepatitis C Virus Related Liver Disease. Am. J. Roentgenol. 189: 819-823 [Abstract] [Full Text]  
• Guha, I N, Parkes, J, Roderick, P R, Harris, S, Rosenberg, W M (2006). Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.. Gut 55: 1650-1660 [Full Text]  
• Cobbold, J F L, Wylezinska, M, Cunningham, C, Crossey, M E, Thomas, H C, Cox, I J, Patel, N, Taylor-Robinson, S D, Pinzani, M (2006). Non-invasive evaluation of hepatic fibrosis using magnetic resonance and ultrasound techniques * Author's reply.. Gut 55: 1670-1670 [Full Text]  
• Lim, A. K. P., Patel, N., Eckersley, R. J., Goldin, R. D., Thomas, H. C., Cosgrove, D. O., Taylor-Robinson, S. D., Blomley, M. J. K. (2006). Hepatic Vein Transit Time of SonoVue: A Comparative Study with Levovist. Radiology 240: 130-135 [Abstract] [Full Text]  
• Cosgrove, D (2006). Developments in ultrasound. Imaging 18: 82-96 [Abstract] [Full Text]